zika
viru
zikv
reemerg
flaviviru
associ
neurolog
disord
spread
rapidli
countri
territori
howev
specif
vaccin
antivir
drug
current
avail
prevent
treat
zikv
infect
report
synthet
peptid
deriv
stem
region
zikv
envelop
protein
design
potent
inhibit
infect
zikv
flavivirus
vitro
show
interact
zikv
surfac
protein
disrupt
integr
viral
membran
penetr
placent
barrier
enter
fetal
tissu
safe
use
pregnant
mice
intraperiton
administr
inhibit
vertic
transmiss
zikv
pregnant
mice
protect
type
type
iii
interferon
receptordefici
mice
lethal
zikv
challeng
thu
potenti
develop
antivir
treatment
zikv
infect
highrisk
popul
particularli
pregnant
women
z
ika
viru
zikv
reemerg
mosquitoborn
flaviviru
envelop
posit
singlestrand
rna
viru
octob
countri
territori
report
continu
vectorborn
transmiss
zikv
http
wwwwhointemergencieszikavirusen
addit
africa
asiapacif
region
america
particularli
south
america
area
risk
zikv
transmiss
concern
zikv
infect
caus
sever
congenit
brain
development
abnorm
includ
microcephali
trigger
syndrom
current
specif
antizikv
therapeut
vaccin
avail
thu
call
develop
effect
safe
antivir
drug
vaccin
worldwid
treatment
prevent
zikv
infect
smallmolecul
compound
cmethyladenosin
cmethyl
nucleosid
epigallocatechin
gallat
well
us
food
drug
administrationapprov
drug
use
clinic
purpos
niclosamid
bortezomib
mycophenol
acid
mefloquin
daptomycin
bromocriptin
found
inhibit
zikv
infect
howev
safeti
smallmolecul
drug
pregnant
women
requir
extens
evalu
murin
antibodi
broad
flavivirusneutr
activ
target
zikv
envelop
e
protein
could
neutral
zikv
infect
vitro
vivo
howev
rel
low
efficaci
requir
human
main
obstacl
develop
human
monoclon
antibodi
mab
broadli
neutral
infect
zikv
strain
howev
high
cost
may
limit
applic
develop
countri
brazil
recent
year
develop
peptid
drug
attract
grow
attent
better
safeti
lower
develop
cost
compar
smallmoleculeand
antibodybas
antivir
drug
previous
identifi
first
highli
potent
antihiv
cpeptid
ref
patent
licens
trimeri
pharmaceut
inc
develop
first
hiv
fusion
inhibitor
enfuvirtid
approv
us
food
drug
administr
treatment
hiv
infect
furthermor
use
enfuvirtid
either
alon
combin
antiretrovir
drug
could
success
prevent
mothertochild
hiv
transmiss
pregnanc
indic
antimicrobi
peptid
could
develop
safe
effect
antivir
therapeut
andor
prophylact
therefor
aim
design
identifi
effect
antizikv
peptid
flavivirion
contain
copi
e
protein
membran
protein
form
e
dimer
complet
cover
viral
surfac
fusion
viral
envelop
host
cell
membran
occur
low
ph
conform
e
protein
chang
dimer
trimer
stem
region
e
protein
proxim
viru
membran
chang
conform
ahelix
random
coil
drive
viral
transmembran
anchor
toward
fusion
loop
stabil
trimer
structur
e
protein
report
peptid
deriv
stem
region
dengu
viru
denv
could
effect
inhibit
fusion
denv
host
cell
induc
hole
format
viral
membran
result
releas
viral
rna
genom
suggest
stem
region
also
serv
import
target
develop
antizikv
drug
present
studi
design
synthes
peptid
deriv
conserv
stem
region
zikv
e
protein
design
found
inhibit
zikv
infect
vitro
vivo
inactiv
zikv
virion
demonstr
abl
penetr
placent
barrier
block
vertic
transmiss
zikv
pregnant
mice
fetus
result
suggest
could
develop
safe
effect
peptid
therapeut
prophylact
treatment
prevent
zikv
infect
highrisk
popul
especi
pregnant
women
ration
design
antizikv
peptid
first
align
aminoacid
sequenc
zikv
e
protein
correspond
fragment
stem
region
denv
e
protein
repres
basi
design
antidenv
peptid
next
align
sequenc
e
protein
flavivirus
includ
japanes
enceph
viru
yellow
fever
viru
yfv
west
nile
viru
found
sequenc
region
highli
conserv
among
flavivirus
aminoacid
sequenc
conserv
fig
supplementari
fig
impli
region
may
play
import
role
flaviviru
infect
final
locat
region
resolut
cryoelectron
microscop
structur
zikv
protein
data
bank
shown
pink
fig
confirm
membraneproxim
stem
region
zikv
e
protein
residu
use
basi
design
synthesi
peptid
scrambl
peptid
determin
antivir
activ
zikv
infect
vero
cell
develop
rapid
sensit
colorimetr
viral
infect
assay
use
cell
count
dojindo
japan
report
zikv
infect
cell
result
obviou
cytopath
effect
cpe
use
assay
test
inhibitori
activ
differ
concentr
infect
zikv
strain
found
inhibit
zikv
infect
dosedepend
manner
inhibitori
concentr
ic
valu
mm
mean
sd
n
cell
fig
mm
n
vero
cell
fig
neg
control
show
signific
inhibit
zikv
infect
also
use
plaqu
reduct
assay
cell
test
antizikv
activ
shown
supplementari
fig
ic
valu
mm
n
suggest
result
deriv
plaqu
reduct
assay
consist
obtain
colorimetr
assay
zikvinduc
cpe
vero
cell
visibl
reduc
mm
concentr
exhibit
inhibitori
activ
fig
line
data
assay
result
immunofluoresc
stain
show
concentr
mm
almost
complet
block
zikv
e
protein
express
vero
cell
fig
evalu
antivir
activ
zikv
strain
shown
tabl
also
effect
inhibit
infect
zikv
strain
flr
cell
ic
valu
mm
respect
suggest
possess
broad
inhibitori
activ
zikv
strain
isol
patient
rhesu
monkey
differ
region
world
result
timeofaddit
experi
supplementari
fig
show
inhibit
zikv
infect
earli
h
post
infect
indic
may
inhibit
infect
zikv
entri
target
cell
follow
investig
whether
could
also
inhibit
infect
mosquitoborn
flavivirus
denv
yfv
found
also
highli
effect
inhibit
infect
yfv
fig
ic
valu
mm
respect
inhibit
infect
pseudotyp
vesicular
stomat
viru
vsv
middl
east
respiratori
syndrom
coronaviru
fig
result
suggest
may
inhibitori
activ
infect
broad
spectrum
flavivirus
bound
e
protein
inactiv
zikv
virion
report
peptid
deriv
stem
region
denv
e
protein
could
inhibit
flaviviru
infect
interact
viru
particl
induc
format
pore
viral
envelop
membran
result
releas
viral
rna
genom
use
similar
approach
investig
whether
could
interact
zikv
e
protein
induc
releas
rna
genom
zikv
virion
first
use
immunofluoresc
stain
assay
show
cell
transfect
could
bound
mous
mab
e
protein
panflavivirus
meanwhil
cell
transfect
empti
vector
show
bind
suggest
zikv
e
protein
express
cell
transfect
fig
use
flow
cytometr
analysi
demonstr
cell
transfect
could
stain
wherea
cell
express
e
protein
show
background
stain
fig
similar
result
obtain
experi
use
zikvinfect
cell
supplementari
fig
result
indic
abl
interact
e
protein
zikv
next
measur
potenti
releas
viral
genom
rna
zikv
use
rnase
digest
assay
shown
fig
genom
rna
untreat
virion
mm
treat
protect
digest
micrococc
nucleas
howev
genom
rna
treat
virion
digest
micrococc
nucleas
doserespons
manner
genom
rna
zikv
virion
treat
mm
digest
micrococc
nucleas
confirm
releas
viral
genom
rna
zikv
virion
treat
dimethylsulfoxid
dmso
mm
dmso
triton
respect
centrifug
sucros
densiti
gradient
previous
describ
amount
genom
rna
e
protein
zikv
fraction
monitor
reversetranscript
quantit
pcr
rtqpcr
western
blot
supplementari
fig
respect
data
western
blot
analys
imag
j
softwar
shown
fig
genom
rna
e
protein
virion
treat
dmso
migrat
fraction
exampl
peak
genom
rna
e
protein
locat
fraction
suggest
virion
treat
dmso
maintain
intact
howev
genom
rna
e
protein
virion
treat
triton
migrat
differ
fraction
peak
genom
rna
e
protein
fraction
respect
indic
virion
complet
destroy
triton
interestingli
peak
genom
rna
e
protein
virion
treat
locat
fraction
respect
result
indic
treatment
may
caus
pore
format
viral
membran
result
releas
viral
genom
rna
pore
next
determin
whether
virion
treat
peptid
inactiv
incub
zikv
room
temperatur
h
separ
treat
zikv
virion
unbound
free
peptid
previous
describ
assess
infect
shown
fig
dosedepend
manner
effect
concentr
mm
n
zikv
treat
concentr
high
mm
retain
infect
fig
suggest
zikv
virion
inactiv
importantli
although
could
disrupt
integr
zikv
membran
show
cytotox
effect
cell
line
vero
test
concentr
high
mm
supplementari
fig
also
show
cytotox
effect
red
blood
cell
isol
mous
peripher
blood
concentr
high
mm
supplementari
fig
could
cross
placent
barrier
pregnant
icr
mice
zikv
cross
placent
barrier
infect
fetu
pregnanc
caus
abnorm
growth
brain
head
fetu
therefor
effect
antizikv
drug
abil
penetr
placent
barrier
infect
pregnant
women
protect
fetu
investig
whether
enter
pregnant
mous
organ
penetr
placenta
enter
fetu
bodi
shown
fig
supplementari
fig
b
fluoresc
signal
shown
site
liver
bladder
locat
dissect
organ
liver
kidney
spleen
heart
suggest
abl
enter
blood
circul
organ
pregnant
mice
averag
radiant
effici
p
cm
sr
mw
cm
liver
p
student
twotail
ttest
bladder
p
student
twotail
test
mice
significantli
higher
phosphatebuff
salin
pb
treat
fig
uterus
pregnant
mice
fetus
uterus
remov
evalu
distribut
specul
signal
seen
uterus
fig
fetus
fig
supplementari
fig
averag
radiant
effici
uterus
p
student
twotail
ttest
fetus
student
twotail
ttest
group
significantli
higher
pb
group
fig
corrobor
data
supplementari
fig
result
suggest
peptid
inject
intraven
intraperiton
ip
penetr
placent
barrier
pregnant
icr
mice
enter
bodi
fetus
safe
pregnant
icr
mice
fetus
zikv
usual
caus
mild
symptom
fever
rash
infect
pregnant
women
caus
congenit
brain
develop
abnorm
fetu
therefor
safeti
antizikv
agent
pregnant
women
taken
consider
accordingli
assess
safeti
pregnant
icr
mice
result
show
bodi
weight
chang
mother
fig
pup
fig
almost
among
six
group
intraven
inject
mg
kg
respect
pb
suggest
inject
caus
visibl
damag
prenat
postpartum
health
pregnant
mice
interfer
normal
growth
pup
find
pup
abnorm
behaviour
level
alanin
aminotransferas
alt
fig
creatinin
fig
sera
mice
pbstreat
group
show
signific
differ
mannwhitney
test
time
point
suggest
inject
high
low
dose
affect
hepat
renal
function
pregnant
mice
use
enzymelink
immunosorb
assay
measur
antibodi
sera
pregnant
mice
week
third
inject
pb
found
antibodi
pbstreat
mice
level
detect
supplementari
fig
result
suggest
poor
immunogen
compar
potenti
histopatholog
chang
mother
pup
among
six
group
shown
fig
haematoxylinandeosinstain
section
liver
kidney
brain
spleen
mice
treat
differ
dose
exhibit
patholog
abnorm
compar
mice
treat
pb
none
sampl
show
evid
cell
degener
necrosi
infiltr
inflammatori
factor
overal
safe
pregnant
icr
mice
fetus
even
dose
high
mg
kg
bodi
weight
higher
provid
protect
zikv
infect
vivo
block
vertic
transmiss
zikv
pregnant
mice
determin
whether
could
protect
vertic
transmiss
zikv
pregnant
mice
infect
zikv
describ
previous
treat
mg
kg
bodi
weight
n
vehicl
control
n
result
show
treatment
could
reduc
viraemia
zikvinfect
pregnant
mice
p
mannwhitney
test
fig
time
viral
rna
load
placenta
pregnant
mice
significantli
lower
vehicletr
mice
p
mannwhitney
test
infect
rate
decreas
fig
interestingli
treatment
result
decreas
infect
rate
fetal
head
p
mannwhitney
test
fig
result
suggest
may
inactiv
zikv
virion
either
virion
penetr
placenta
fetu
thu
reduc
infect
rate
fetus
well
protect
vertic
transmiss
zikv
pregnant
mice
protect
mice
lethal
zikv
challeng
final
antivir
efficaci
confirm
recent
establish
type
interferon
receptordefici
type
iii
interferon
receptordefici
mous
model
thirtyon
pregnant
icr
mice
assign
randomli
six
group
inject
intraven
pb
n
pb
contain
escal
dose
mg
kg
n
mg
kg
n
mg
kg
n
mg
kg
n
mg
kg
n
everi
day
consecut
day
data
mean
sd
articl
zikv
infect
one
hour
inocul
zikv
ip
mice
treat
vehicl
shown
fig
mice
treat
vehicl
develop
neurolog
symptom
day
post
inocul
final
display
mortal
rate
day
post
inocul
contrast
treatment
protect
mice
death
caus
zikv
infect
survivor
neurolog
symptom
treatment
also
significantli
prolong
mean
surviv
time
mst
day
end
experi
p
logrank
mantel
cox
test
viral
load
mice
day
post
infect
dpi
lower
vehicletr
mice
p
mannwhitney
test
fig
similarli
treatment
protect
mice
death
caus
subcutan
administr
zikv
significantli
prolong
mst
day
end
experi
p
logrank
mantel
cox
test
fig
viral
load
mice
dpi
lower
vehicletr
mice
p
mannwhitney
test
fig
twentyfour
hour
inocul
zikv
treatment
still
could
protect
mice
death
p
logrank
mantel
cox
test
supplementari
fig
viral
load
mice
dpi
lower
vehicletr
mice
p
mannwhitney
test
supplementari
fig
although
inactiv
zikv
earli
stage
viral
replic
consecut
inject
zikv
penetr
cell
could
still
provid
protect
infect
mice
possibl
inactiv
newli
produc
zikv
virion
prevent
infect
target
cell
report
peptid
deriv
stem
region
denv
e
protein
inhibit
infect
denv
type
flavivirus
includ
russian
spring
summer
enceph
viru
central
european
enceph
viru
west
nile
viru
howev
best
knowledg
none
peptid
report
effect
zikv
infect
vitro
vivo
develop
preclin
clinic
studi
show
peptid
deriv
stem
region
zikv
e
protein
highli
effect
inhibit
vitro
infect
zikv
vero
cell
flavivirus
yfv
importantli
intraperiton
administr
protect
pregnant
mice
vertic
transmiss
zikv
protect
mice
suscept
zikv
infect
lethal
zikv
challeng
mechan
peptid
deriv
stem
region
flaviviru
inhibit
infect
broad
spectrum
flavivirus
remain
point
controversi
report
peptid
mimic
fragment
stem
region
denv
e
protein
act
like
disrupt
denv
membran
possibl
induc
hole
format
lead
releas
viral
genom
similarli
found
peptid
could
bind
e
protein
zikv
disrupt
integr
zikv
membran
result
inactiv
virion
howev
detail
molecular
mechan
signal
pathway
far
elucid
would
explain
bind
e
protein
disrupt
viral
cell
membran
electrostat
hydrophob
interact
viral
capsid
dynam
studi
mechan
investig
beyond
scope
present
paper
interestingli
disrupt
flaviviru
membran
effect
integr
pseudotyp
vsv
merscov
membran
cell
membran
possibl
lipid
composit
protein
compon
charg
hydrophob
among
membran
differ
especi
flaviviru
membran
deriv
intern
endoplasm
reticulum
membran
infect
cell
nevertheless
exclud
put
mechan
action
involv
antizikv
activ
inhibit
membran
fusion
howev
suffici
evid
conclud
similar
mechan
vector
aed
aegypti
case
coinfect
zikv
denv
arbovirus
chikungunya
viru
report
moreov
preexist
denv
antibodi
may
enhanc
zikv
infect
antibodydepend
enhanc
ade
effect
phenomenon
antibodi
certain
flaviviru
enhanc
infect
heterogen
viru
similar
denv
zikv
antibodi
may
also
induc
ade
effect
zikv
denv
infect
modif
antizikv
antibodi
decreas
bind
fcgr
may
reduc
risk
ade
effect
howev
may
increas
cost
antibodi
antivir
activ
broad
spectrum
flavivirus
may
favour
patient
infect
denv
zikv
simultan
without
concern
ade
effect
viral
inactiv
advantag
compar
smallmolecul
antivir
drug
target
viral
replic
stage
insid
target
cell
proteas
inhibitor
inhibit
zikv
infect
viral
entri
therefor
benefici
treatment
zikv
viraemia
especi
women
childbear
age
partner
low
toxic
vitro
vivo
ensur
safeti
pregnant
women
fetus
proteas
inhibitor
hand
work
viru
enter
cell
turn
may
allow
influx
virion
fetus
without
specif
zikv
proteas
inhibitor
may
caus
harm
effect
highrisk
pregnant
women
therefor
combin
use
proteas
inhibitor
treatment
zikv
infect
may
synergist
effect
result
reduct
dose
thu
toxic
proteas
inhibitor
actual
zikv
infect
pregnant
woman
caus
sever
congenit
brain
development
abnorm
fetu
well
infect
testi
caus
damag
lead
male
infertil
therefor
also
detect
distribut
genit
organ
male
mice
supplementari
fig
show
could
distribut
genit
organ
male
mice
suggest
may
prevent
testi
damag
caus
zikv
howev
experi
need
carri
confirm
find
versatil
tradit
drug
may
convert
bullet
target
viru
fetal
brain
coupl
bloodbrain
barrier
shuttl
peptid
glutathion
peptid
deriv
transferrin
lowdens
lipoprotein
ldlr
may
acquir
abil
penetr
fetal
bloodbrain
barrier
also
disclos
peptid
drug
unfavour
featur
immunogen
short
halflif
studi
show
intraperiton
administr
peptid
without
adjuv
induc
antibodi
halflif
time
h
supplementari
fig
supplementari
tabl
nowaday
mani
way
found
prolong
halflif
peptid
drug
protect
n
c
termini
nacetyl
camid
substitut
lamino
acid
damino
acid
modif
amino
acid
polyethylen
glycol
peg
albumin
lipopeptid
conclus
peptid
stem
region
zikv
envelop
protein
exhibit
potent
antizikv
activ
excel
safeti
pharmacolog
profil
indic
potenti
develop
novel
antivir
drug
treat
zikv
infect
highrisk
popul
particularli
pregnant
women
assay
antivir
activ
peptid
dissolv
dmso
serial
dilut
serumfre
dmem
ml
viru
zikv
ad
ml
peptid
solut
incub
h
mixtur
ad
cell
seed
plate
follow
incub
h
cultur
supernat
replac
fresh
dmem
contain
fb
day
later
zikvinduc
cpe
becam
evid
antivir
activ
detect
use
cell
count
dojindo
japan
accord
instruct
manual
data
collect
micropl
reader
infinit
tecan
usa
pseudotyp
vsv
merscov
set
unrel
viru
control
prepar
previous
describ
briefli
cell
cotransfect
plasmid
encod
merscov
protein
provid
dr
lani
du
new
york
blood
center
vsvg
protein
gift
dr
yan
wang
shanghai
institut
biolog
scienc
obtain
nih
aid
reagent
program
use
vigofect
vigor
biotechnolog
beij
china
supernat
contain
pseudotyp
merscov
vsv
collect
h
post
transfect
cell
infect
control
virus
describ
day
inhibitori
activ
pseudoviru
infect
measur
use
luciferas
assay
system
accord
instruct
manual
promega
co
madison
wi
immunofluoresc
stain
determin
inhibitori
activ
zikv
infect
vero
cell
cell
seed
onto
coverslip
plate
day
infect
zikv
mix
equal
volum
serial
dilut
mm
mm
serumfre
dmem
incub
h
mixtur
ad
cell
twelv
hour
later
cultur
supernat
replac
dmem
contain
fb
day
cell
fix
paraformaldehyd
pfa
sigmaaldrich
st
loui
mo
perfor
triton
block
bsa
amresco
llc
solon
oh
cell
incub
overnight
anti
mab
mg
ml
provid
dr
lifang
jiang
danyun
fang
sun
yatsen
univers
five
wash
cell
incub
alexa
fluor
donkey
antimous
igg
thermo
fisher
scientif
wilmington
de
usa
room
temperatur
h
five
wash
coverslip
seal
prolong
gold
antifad
reagent
thermo
fisher
scientif
scan
leica
confoc
microscop
detect
express
zikv
e
protein
cell
seed
coverslip
transfect
provid
dr
lani
du
new
york
blood
center
empti
vector
thermo
fisher
scientif
use
vigofect
cultur
h
immunofluoresc
stain
perform
use
anti
mab
describ
test
bind
zikvinfect
cell
cell
seed
coverslip
zikvor
mockinfect
fix
pfa
perfor
triton
block
bsa
cell
incub
anti
mab
five
wash
cell
incub
alexa
fluor
donkey
antimous
antibodi
room
temperatur
h
anoth
five
wash
coverslip
seal
scan
leica
confoc
microscop
flow
cytometri
assay
cell
seed
sixwel
plate
cultur
h
cell
transfect
vigofect
h
cell
digest
edta
buffer
obtain
singlecel
suspens
treat
nm
min
untreat
cell
test
blank
control
three
wash
data
bind
cell
without
e
protein
express
collect
bd
accuri
flow
cytomet
rnase
digest
assay
rtqpcr
releas
genom
rna
zikv
particl
detect
rnase
digest
assay
rtqpcr
previous
describ
briefli
plaqueform
unit
pfu
zikv
incub
room
temperatur
h
releas
genom
rna
treat
zikv
particl
digest
micrococc
nucleas
new
england
biolab
h
inactiv
residu
rnase
undigest
genom
rna
intact
viral
particl
extract
use
qiagen
qiaamp
viral
rna
mini
kit
valencia
ca
revers
use
rt
reagent
kit
takara
bio
shiga
japan
zikv
rna
genom
quantifi
sybr
premixextaqii
tlirnas
h
plu
takara
bio
master
cycler
ep
realplex
pcr
system
eppendorf
hamburg
germani
accord
manufactur
instruct
follow
primer
use
detect
rna
sequenc
viral
genom
code
precursor
membran
protein
prm
e
capsid
cap
protein
respect
fig
sucros
densiti
gradient
assay
approxim
pfu
zikv
treat
pb
contain
vv
dmso
mm
pb
contain
vv
dmso
pb
contain
vv
triton
h
treat
virion
gentli
load
top
sucros
step
gradient
centrifug
swing
bucket
rotor
beckman
coulter
brea
ca
optima
xp
ultracentrifug
beckman
coulter
h
fraction
top
bottom
collect
assay
viral
genom
rna
rtqpcr
e
protein
western
blot
anti
mab
mg
ml
use
detect
e
protein
assay
detect
inactiv
zikv
virion
inactiv
zikv
particl
separ
detect
previous
describ
briefli
ml
grade
concentr
mm
ad
ml
zikv
pfu
per
ml
follow
incub
room
temperatur
h
amresco
nacl
ad
treat
viru
final
concentr
respect
incub
ice
h
mixtur
centrifug
h
supernat
contain
free
peptid
remov
pellet
contain
viral
particl
wash
pb
contain
mg
ml
bsa
amresco
centrifug
pellet
resuspend
ml
dmem
contain
fb
infect
zikv
particl
pellet
determin
use
cell
describ
vivo
fluoresc
imag
six
pregnant
icr
mice
week
old
assign
randomli
two
group
inject
intraven
mg
ml
pb
n
ml
pb
without
peptid
n
control
background
fluoresc
measur
one
hour
later
mice
imag
distribut
ivi
lumina
k
seri
iii
vivo
imag
system
perkinelm
waltham
radiant
effici
p
cm
sr
mw
cm
calcul
live
imag
softwar
determin
distribut
organ
pregnant
mice
kill
intraperiton
inject
sodium
pentobarbit
dissect
liver
kidney
spleen
heart
uterus
fetus
imag
averag
radiant
effici
calcul
fetus
uterus
two
group
appli
pfafix
paraffin
section
demonstr
distribut
placenta
fetu
safeti
pregnant
icr
mice
fetus
thirtyon
pregnant
icr
mice
week
old
assign
randomli
six
group
inject
intraven
n
n
n
n
mg
kg
n
bodi
weight
pb
n
control
everi
day
consecut
day
bodi
weight
chang
mother
differ
prenat
postnat
time
point
pup
variou
postnat
time
point
monitor
alt
creatinin
sera
collect
tail
measur
use
alt
creatinin
assay
kit
njjcbio
nanj
china
first
inject
h
day
respect
third
inject
specif
antibodi
respons
elicit
mice
evalu
enzymelink
immunosorb
assay
week
third
inject
pb
three
week
pup
born
two
mother
pup
group
kill
liver
kidney
spleen
brain
collect
haematoxylin
eosin
stain
anim
studi
icr
mice
carri
accord
ethic
guidelin
approv
institut
laboratori
anim
care
use
committe
fudan
univers
antivir
efficaci
pregnant
mice
antivir
efficaci
pregnant
mice
evalu
use
method
previous
report
briefli
pregnant
mice
week
old
assign
randomli
two
group
infect
ip
pfu
zikv
one
hour
later
infect
mice
ip
administ
mg
kg
bodi
weight
n
vehicl
control
n
day
post
infect
mice
retroorbit
bled
measur
viraemia
rtqpcr
two
embryo
pregnant
mous
randomli
collect
viral
rna
load
placenta
fetal
head
collect
embryo
determin
rtqpcr
antivir
efficaci
mice
antivir
efficaci
mous
model
evalu
previous
report
briefli
sixteen
femal
mice
assign
randomli
two
group
infect
ip
pfu
zikv
infect
mice
ip
administ
mg
kg
bodi
weight
n
vehicl
control
n
everi
day
consecut
dpi
mice
observ
daili
sign
ill
mortal
anim
surviv
day
deem
protect
meanwhil
viral
rna
load
sera
day
dpi
measur
rtqpcr
twelv
sexmatch
mice
assign
randomli
two
group
infect
pfu
zikv
via
subcutan
rout
footpad
infect
mice
ip
administ
mg
kg
bodi
weight
n
vehicl
control
n
everi
day
consecut
dpi
observ
examin
mice
done
describ
anim
studi
infecti
zikv
conduct
biosafeti
level
facil
beij
institut
microbiolog
epidemiolog
shanghai
public
health
clinic
center
institut
biosafeti
committe
approv
statist
analysi
statist
method
perform
follow
logrank
mantel
cox
test
compar
mst
zikvinfect
mice
treat
vehicl
student
unpair
twotail
ttest
monitor
distribut
icr
mice
nonparametr
mannwhitney
test
examin
effect
level
alt
creatinin
group
pb
group
one
time
point
nonparametr
mannwhitney
test
also
determin
differ
viral
rna
load
sera
mice
treat
vehicl
statist
analys
carri
spss
graphpad
prism
softwar
data
avail
relev
data
avail
author
request
